Gene therapy using the herpes simplex virus thymidine kinase (HSV-TK) gene combined with an anti-herpes drug, ganciclovir (GCV), has been applied for human diseases, especially for cancer treatment. However, bone marrow toxicity has been the most consistent adverse effect of GCV treatment in clinical settings. We evaluated the cytotoxic activity of a novel guanosine analog, (1ЈS,2ЈR)-9{[1Ј,2Ј-bis(hydroxymethyl)cycloprop-1Ј-yl]methyl}guanine (A-5021), against retrovirus-mediated HSV-TK gene-transduced human lung cancer cells. The bone marrow toxicity of A-5021 and GCV was studied by colony formation assay in both rodent and human bone marrow specimens. We demonstrated that A-5021 had potent cytotoxic activity equal to that of GCV against the retroviral vector-mediated HSV-TK gene-transduced lung cancer cell lines. Further, phosphorylated A-5021 could be transferred to neighboring cells, and this analog killed HSV-TK Ϫ neighboring cells, as was the case for GCV. In contrast, A-5021 did not exhibit an inhibitory effect on bone marrow progenitor cells and colony formation (the 50% inhibitory concentration of the colony-forming units in culture ϭ Ͼ100 g/mL in human bone marrow specimens and Ͼ66 g/mL in rodent bone marrow specimens). These results indicate that A-5021 has potent cytotoxic activity as a nucleoside analog for gene therapy using HSV-TK gene, and can be used much more safely than GCV. Cancer Gene Therapy (2000) 7, 557-562
T ransduction of target cells with a gene whose product can convert a nontoxic prodrug into a toxic metabolite within the cells is one of the adopted therapeutic strategies for gene therapy. 1 In the first protocol to be approved using this strategy for human gene therapy, brain tumors were transduced with a retroviral vector expressing the herpes simplex virus thymidine kinase (HSV-TK) gene, and an anti-herpes drug ganciclovir (GCV) was chosen for the study. The rationale behind this is that acyclovir (ACV) and GCV are nucleoside analogs specifically converted by HSV-TK to a toxic form capable of inhibiting DNA synthesis or disrupting cellular DNA replication; however, they are poor substrates for the TK of mammalian cells. [2] [3] [4] We reported previously that the cytotoxic activity of GCV was three orders of magnitude greater than that of ACV against HSV-TK gene-transduced human lung cancer cells. 5 However, several reports demonstrated that prolonged administration of GCV causes hematological toxicity, and neutropenia in particular. The incidence of leukopenia occurred in as many as 40 -50% of bone marrow transplantation recipients. 6 -8 The novel guanosine analog (1ЈS,2ЈR)-9{[1Ј,2Ј-bis(hydroxymethyl)cycloprop-1Ј-yl]methyl}guanine (A-5021) has potent antiviral activity against HSV-1, HSV-2, Varicella zoster virus, and human cytomegalovirus. 9, 10 A-5021 has highly selective anti-herpetic activity and was selectively phosphorylated by viral TK in herpes virusinfected cells. The agent showed reduced antiviral activity against TK-deficient strains of HSV. The anti-herpetic activity of A-5021 was the most potent in comparison with ACV and penciclovir, which are nucleoside analogs having anti-herpes virus activities. 9 In addition, A-5021 was suggested to be less toxic to bone marrow progenitor cells than ACV and penciclovir. In this study, we evaluated the cytotoxic activity of A-5021 against HSV-TK gene-transduced human lung cancer cells with retroviral vector. The bone marrow toxicity of A-5021 and GCV was also compared in colony forma-tion assay, and we evaluated the efficacy and the safety of A-5021 as a better alternative than GCV for gene therapy using HSV-TK gene.
MATERIALS AND METHODS

Reagents
A-5021 (Fig 1) was prepared at Ajinomoto Co., Inc. (Kawasaki, Japan). GCV (9-[(1,3,-dihydroxy-2-propoxy)methyl] guanine) was obtained from Tanabe Pharmaceutical Co. (Osaka, Japan). The neomycin analog G418 was obtained from Life Technologies (Gaithersburg, Md). Recombinant human granulocyte-macrophage colony-stimulating factor was provided as a generous gift from Kirin Brewery Co. (Tokyo, Japan).
Tissue culture and cell lines
The human lung cancer cell lines RERF-LC-MA (small cell carcinoma of the lung), RERF-LC-MS (adenocarcinoma of the lung), and A549 (alveolar cell carcinoma of the lung), as well as the murine lung cancer cell line 3LLSA, were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). All cell lines except for the 3LLSA cell line were maintained in Eagle's minimum essential medium (MEM) supplemented with 1% nonessential amino acids, 1% L-glutamine, 1% sodium pyruvate, penicillin (50 U/mL), streptomycin (50 g/mL), and 10% fetal calf serum (FCS) (MEM/FCS). 3LLSA was maintained in RPMI 1640 with 1% nonessential amino acids, 1% L-glutamine, 1% sodium pyruvate, penicillin (50 U/mL), streptomycin (50 g/mL), and 10% FCS (RPMI/ FCS). The cell lines RERF-LC-MS, RERF-LC-MA, A549, and 3LLSA were transduced with the recombinant retroviral vector pLTRNL. This was derived from Moloney murine leukemia virus backbone, which consisted of the long terminal repeat, HSV-TK cDNA, and the neomycin-resistant gene.
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The cell lines were plated in a 24-well tissue culture plate and transduced 24 hours later by exposure for 48 hours to viral vector at a virus titer of 5 ϫ 10 4 colony-forming units (CFU)/mL from a PA317/LTRNL vector-producer line in the presence of 4 g/mL polybrene. Next, cells were cultured with MEM/FCS or RPMI/FCS containing G418 (800 g/mL and 600 g/mL, respectively). After 2 weeks of selection, G418-resistant clones of RERF-LC-MS-LTRNL, RERF-LC-MA-LTRNL, A549-LTRNL, and 3LLSA-LTRNL were selected randomly from the surviving colonies and used in the following experiments.
Measurement of cytotoxicity
The cytotoxicity of the nucleoside analogs A-5021 and GCV was determined using a tetrazolium-based colorimetric assay (3-(4,5-diethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay). 5 A single-cell suspension obtained by trypsinization was seeded at 2 ϫ 10 3 cells/well in 96-well tissue culture plates. The assay is dependent upon the cellular reduction of a tetrazolium salt, MTT, by the mitochondrial dehydrogenase of viable cells to a blue formazan product that can be measured spectrophotometrically. Cells were incubated for 4 days with or without nucleoside analogs, and 0.5 mg/mL (final concentration) of MTT was then added to each well. After 3-4 hours incubation at 37°C with MTT, the unreacted MTT and medium were removed, and 150 L of dimethylsulfoxide was added to solubilize the MTT formazan. After shaking the plates, the optical density (OD) of each well was measured with a microplate spectrophotometer (EAR 400 AT, SLT Lab Instruments, Austria) equipped with a 540-nm filter. The spectrophotometer was calibrated at 0 absorbance using wells that had only contained medium and MTT. The OD reading of control wells contained cells and MTT (maximum dye reduction). The percentage of cytotoxicity was calculated according to the following equation: % cytotoxicity ϭ (1 Ϫ [OD drugtreated/OD control]) ϫ 100. All tests were performed in six samples, and mean values were calculated.
Measurement of bystander effect in vitro
Bystander experiments were performed by coculturing the parental wild-type (wt) tumor cells with the HSV-TK genetransduced tumor cells. 12 The wt tumor cells were seeded at 10 5 cells in 35 mm dishes mixed with 10 5 , 10 4 , and 10 3 HSV-TK gene-transduced cells (mixture ratios: 1:1, 10:1, and 100:1, respectively). After a 12-hour incubation of the cells, they were cultured with or without 5 g/mL (final concentration) of A-5021 or 5 g/mL of GCV for 5 days. Culture medium with or without A-5021 or GCV was replaced every 2 days. Next, cells were harvested, and the number of viable cells was determined using the dye exclusion method. The parental wt cells alone or HSV-TK gene-transduced cells alone were cultured in the medium with or without A-5021 or GCV as a control.
Colony assays
Mouse bone marrow cells were isolated from the femurs of 10-week-old female C57BL/6 mice supplied from the Institute for Laboratory Animal Research of Nagoya University School of Medicine. As for the CFU in culture (CFU-C) assay, a suspension of bone marrow cells containing 4 ϫ 10 4 cells/mL was prepared in Iscove's modified Dulbecco's medium containing 0.8% methyl cellulose, 20% FCS, 200 U of murine interleukin-3 per milliliter, and test compound; next, the suspension was seeded onto a 35-mm diameter Petri dish at a volume of 1 mL. After 7 days of incubation at 37°C in a humidified atmosphere of 5% CO 2 /95% air, the number of colonies formed was counted microscopically. 9 As for the CFU in spleen (CFU-S) assay, a suspension of bone marrow cells (1 ϫ 10 6 cells/mL) was cultured in RPMI/FCS with test compound for 24 hours at 37°C in a humidified atmosphere of 5% CO 2 /95% air. After washing the cells, the bone marrow cells (1 ϫ 10 6 cells) were injected intravenously into C57BL/6 mice irradiated with 850 rad of x-ray. Spleens were removed at 7 days postinjection and stained with Bouin's solution. Next, the macroscopic spleen colonies were counted. 13, 14 Human bone marrow samples were obtained with informed consent from normal volunteers. Mononuclear cells were collected by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient centrifugation. They were washed and resuspended in RPMI 1640 with 20% FCS at 1 ϫ 10 6 cells/mL. After testing by trypan blue dye exclusion, viable marrow cells were grown at 2 ϫ 10 5 cells/mL in semisolid agar composed of ␣-MEM containing 0.3% agar supplemented with 20% FCS, 1% dialyzed bovine serum albumin (Sigma), and recombinant human granulocyte-macrophage colony-stimulating factor (final concentration at 10 ng/mL). A total of 500 L of semisolid agar in a 35-mm culture dish was incubated in triplicate for 10 days at 37°C in a humidified atmosphere of 5% CO 2 ; the number of colonies formed was counted microscopically.
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RESULTS
Effect of A-5021 and GCV on HSV-TK genetransduced clones
We examined the cytotoxic activity of GCV for HSV-TK gene-transduced lung cancer cell lines. As shown in Figure 2 , the cytotoxic activities of A-5021 and GCV were dose-dependent against HSV-TK gene-transduced clones of both mouse (3LLSA-LTRNL) and human (RERF-LC-MA-LTRNL, RERF-LC-MS-LTRNL, and A549-LTRNL) lung carcinoma cell lines, and less toxic to wt cell lines. Although the values of IC 50 (defined as a dose required for 50% cytotoxicity) varied in each cell line, the HSV-TK gene-transduced clones clearly showed A-5021-and GCV-dependent cytotoxicities compared with control cell lines. The cytotoxic activity of A-5021 was not different from that of GCV in each HSV-TK gene-transduced cell line. Furthermore, the time course of the cytotoxic activity of A-5021 was the same as that of GCV (data not shown). These results indicate that A-5021 has potent cytotoxic activity against retroviral vector-mediated HSV-TK gene-transduced lung cancer cell lines, and its cytotoxic activity is equal to that of GCV. Bone marrow toxicity of A-5021 and GCV To evaluate the adverse effect of A-5021, we examined its toxic effect on normal bone marrow cells in comparison with GCV. Figure 4A shows the cytotoxic effect of nucleoside analogs on mouse bone marrow cells using a CFU-C assay. The value of IC 50 (defined as the dose required for 50% inhibition of colony formation) was 18 g/mL for GCV. In contrast to GCV, A-5021 did not exhibit any inhibitory effect on bone marrow progenitor cells and colony formation (IC 50 ϭ Ͼ66 g/mL). Furthermore, we investigated the effect of A-5021 on in vivo reconstituting cells, which potentiate to form colonies in mouse spleen. Figure 5 shows the respective effects of A-5021 and GCV on the CFU-S assay. A-5021 (100 g/mL) did not affect the in vivo reconstituting cells in mouse bone marrow cells as assessed by the CFU-S assay, although GCV (100 g/mL) suppressed the number of CFU (spleen). In addition, the in vivo toxicity studies using rats and dogs treated with A-5021 did not B-1,B-2,B-3) . Bone marrow cells were cultured with A-5021 (F) or GCV (E). Results are expressed as the percentage of the number of colonies compared with the colonies formed without A-5021 and GCV. Each value represents the mean Ϯ SD in triplicate assays. Figure 5 . Effect of A-5021 and GCV on CFU-S assay of mouse bone marrow cells. Bone marrow cells were cultured with or without GCV (100 g/mL) or A-5021 (100 g/mL). The cells were injected intravenously into C57BL/6 mice irradiated with 850 rad of x-ray. After 7 days of injection, macroscopic spleen colonies were counted. The filled bar depicts the mean Ϯ SD (n ϭ 4). Statistical differences were analyzed with the Mann-Whitney U test. A P value of Ͻ.05 was considered statistically significant.
Bystander tumoricidal effect of A-5021 and GCV on lung cancer cell lines in vitro
show any bone marrow toxicity (Varita T. and Tsubuku S., unpublished data).
To confirm the above data and to validate these findings in humans, we obtained normal human bone marrow cells from three volunteers. Figure 4 , B-1 through B-3, shows the data obtained from these three cases. GCV markedly suppressed colony formation at the dose of 50 g/mL and inhibited it completely at the dose of 100 g/mL. However, A-5021 has no effect on the colony formation of human bone marrow cells even at the dose of 100 g/mL. These findings indicate that A-5021 is less toxic to bone marrow cells than GCV.
DISCUSSION
Human gene therapy using HSV-TK gene combined with GCV was originally approved as a cancer gene therapy. Thereafter, the HSV-TK system has been applied, and new clinical protocols, such as in vivo control of the target cells transferred as an allogeneic graft after the ex vivo transduction of HSV-TK gene, continue to be proposed. 16, 17 In addition to the development of HSV-TK gene transduction into target cells, new drugs are being designed in place of GCV. The lipophilic elaidic acid ester of GCV is one of the reported candidates, and its superior cytostatic activity has been explained by the prolonged intracellular retention of GCV metabolites. 18 Furthermore, recent reports by Tong et al 19 showed that high-dose ACV may be used instead of GCV for the treatment of HSV-TK gene-transduced ovarian carcinoma cells without increasing toxicity.
We demonstrated in this study that a novel guanosine analog, A-5021, showed equal cytotoxic activity to GCV in HSV-TK gene-transduced cells. A-5021 also had potent activity for the bystander tumoricidal effect, a well-known phenomenon observed in HSV-TK genetransduced cells with GCV administration. Our previous report showed that the cytotoxic activity of GCV was three orders of magnitude greater than that of ACV against HSV-TK gene-transduced cancer cells. 5 In fact, almost all of the gene therapy strategies proposed for the use of HSV-TK gene transduction have adopted GCV as a nucleoside analog. 1 Although GCV and ACV show the same levels of anti-herpetic activity, GCV is phosphorylated not only in HSV-infected cells but also in HSV noninfected cells, resulting in the low selectivity index (determined as the ratio of the drug concentrations for 50% inhibition of cell proliferation to that of virus plaque formation) of GCV compared with ACV. The phosphorylation of GCV in HSV-TK Ϫ cells may cause the hematological toxicity due to prolonged administration.
Conversely, A-5021 has been reported to show stronger anti-herpetic activity against wt herpes viruses than ACV, and the values of 50% inhibition of plaque formation of HSV-1 in MRC-5 cells (fibroblast-like cell lines derived from normal embryonic lung tissue) for A-5021 and ACV were 0.011 g/mL and 0.27 g/mL, respectively. 9 As the anti-herpetic activity levels of GCV and ACV have been shown to be the same, A-5021 is thought to be stronger than GCV in this regard. However, there is no report in which the anti-herpetic activity of A-5021 was compared directly with GCV. The mode of chain termination of A-5021 was different from that of ACV, and tandem incorporation of A-5021 terminates DNA elongation and causes the significant conformational distortion of DNA observed at the site of GCV incorporation. 10 Furthermore, we demonstrated here that A-5021 had less toxicity to both rodent and human bone marrow cells compared with GCV. This may be a great advantage not only for patients with herpes virus infection but also for those receiving gene therapy using HSV-TK gene, followed by prolonged administration of anti-herpetic nucleoside analogs.
We reported previously that the HSV-TK system with GCV would be applicable to human lung cancer cells from small cell carcinoma and non-small cell carcinoma on the basis of the IC 50 values and the existence of gap junctional communication. 11, 12 We showed that A-5021 could be an alternate to GCV in gene therapy using the HSV-TK system both in small cell carcinoma and nonsmall cell carcinoma, taking advantage of the decreased risk for bone marrow suppression. Taking these findings into consideration, we suggested that A-5021 has potent cytotoxic activity and can be used much more safely than GCV as a nucleoside analog for gene therapy using HSV-TK gene.
